ArticleCell2022
Mucus-degrading Bacteroides link carbapenems to aggravated graft-versus-host disease.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07791849 (Comparative Effect of Proton Pump Inhibitors and Gastric Mucosal Protective Agents on Acute Graft-versus-Host Disease Post-Transplantation), which is not on this map. Cited by 73 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 2 pooled it
14.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparative Effect of Proton Pump Inhibitors and Gastric Mucosal Protective Agents on Acute Graft-versus-Host Disease Post-Transplantation: A Prospective Randomized Controlled Trial
Who cites it
73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 106 citations in OpenAlex.
- Safety and efficacy of fecal microbial transplantation for the prevention and treatment of acute graft-versus-host disease: a meta-analysis.Frontiers in microbiology · 2026Pooled it
- Gut microbiome alterations and their clinical and biological implications in ovarian cancer: a systematic review.Frontiers in oncology · 2025Pooled it
- Tildrakizumab for the prophylaxis of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Blood advances · 2026Trial
- Trial
- Fecal microbiota transplantation to prevent acute graft-versus-host disease: pre-planned interim analysis of donor effect.Nature communications · 2025Trial
- Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- The gut microbiome in graft-versus-host disease: mechanisms of immune modulation and therapeutic approaches.Gut microbes · 2026Review
- Fecal Microbiota Transplantation and Microbiota-Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions.Clinical pharmacology and therapeutics · 2026Review
- The Role of the Gut Microbiota in Allogeneic Hematopoietic Cell Transplantation.American journal of hematology · 2026Review
- Clinical translational research on stem cell products: prospects and challenges.Signal transduction and targeted therapy · 2026Review
- The intestinal microbiota as a key modulator of acute graft-versus-host disease.Nature reviews. Cancer · 2026Review
- Intestinal microbiota dynamics in postoperative delirium following cardiac surgery with cardiopulmonary bypass: an observational study.BMC anesthesiology · 2026Observational
- Degradation of mucinbioRxiv : the preprint server for biology · 2026Article
- Scale reliant mixed effects models enhance microbiome data analysis.Microbiome · 2026Article
- Fecal carbohydrate-degrading bacteria are associated with reduced incidence of lower gastrointestinal GVHD.Blood advances · 2026Article
- Disrupted gut microbiome networks and unhealthy behaviors predict metabolic dysfunction in children and adolescents in the long term.iScience · 2026Article
- Re-evaluating gut microbiome signatures of post-antibiotic dietary fiber intake in a large adult cohort.BMC research notes · 2026Article
- Antibiotic risk score for acute graft-versus-host disease.Blood advances · 2026Article
- Dietary ellagic acid inhibiting gastrointestinal pathogens by modulation of microbiome-metabolite-immune axis.Natural products and bioprospecting · 2026Article
- Paeoniflorin prevents acute graft-versus-host disease while preserving graft-versus-tumor effects.Frontiers in immunology · 2026Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors at 5 institutions in 1 country.
Eiko HayaseDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Tomo HayaseDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Mohamed A JamalDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Takahiko MiyamaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Chia-Chi ChangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Miriam R OrtegaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Saira S AhmedDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Jennifer L KarmouchDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Christopher A SanchezDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Alexandria N BrownDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Rawan K El-HimriDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Ivonne I FloresDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Lauren K McDanielDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Dung PhamDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Taylor HalseyDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Annette C FrenkDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Valerie A ChapaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Brooke E HeckelDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Yimei JinDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Wen-Bin TsaiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Rishika PrasadDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Lin TanDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA; Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Lucas VeillonDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA; Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Nadim J AjamiDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Jennifer A WargoDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Jessica Galloway-PeñaDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Veterinary Pathobiology, Interdisciplinary Program in Genetics, Texas A&M University, College Station, TX 77843, USA.
Samuel ShelburneDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Roy F ChemalyDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Lauren DaveyDepartment of Molecular Genetics and Microbiology, Duke University, Durham, NC 27710, USA.
Robert W P GlowackiDepartment of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Chen LiuDepartment of Pathology, Yale School of Medicine, New Haven, CT 06520, USA.
Gabriela RondonDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Amin M AlousiDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Jeffrey J MolldremDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Richard E ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Elizabeth J ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Raphael H ValdiviaDepartment of Molecular Genetics and Microbiology, Duke University, Durham, NC 27710, USA.
Eric C MartensDepartment of Microbiology & Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Philip L LorenziDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA; Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Robert R JenqDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; CPRIT Scholar in Cancer Research, Houston, TX, USA. Electronic address: rrjenq@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USDuke University · USUniversity of Michigan–Ann Arbor · USTexas A&M University · USYale University · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MWomen's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8MProtecting colonic mucus to mitigate acute intestinal graft-versus-host diseaseR01HL124112 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI JENQ, ROBERT · 2015 to 2024
$6.8MLow dietary fiber and gut microbiota-induced mucus layer erosion as IBD triggersR01DK118024 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRACE Y. CHEN, Eric C Martens · 2018 to 2026
$4.9MUnraveling the enzymatic pathway of gut bacterial mucus degradation to treat inflammationR01DK125445 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOROPATKIN, NICOLE M, MARTENS, ERIC C · 2020 to 2023
$2.2MIdentifying Risk Factors for Antibiotic Resistance via Integration of Epidemiology and MetagenomicsK01AI143881 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GALLOWAY-PENA, JESSICA RHEA · 2019 to 2023
$545kNCI NIH HHS P30 CA014236NCI NIH HHS P30 CA016672NHLBI NIH HHS R01 HL124112NIAID NIH HHS K01 AI143881NIDDK NIH HHS R01 DK118024NIDDK NIH HHS R01 DK125445
Abstract
The intestinal microbiota is an important modulator of graft-versus-host disease (GVHD), which often complicates allogeneic hematopoietic stem cell transplantation (allo-HSCT). Broad-spectrum antibiotics such as carbapenems increase the risk for intestinal GVHD, but mechanisms are not well understood. In this study, we found that treatment with meropenem, a commonly used carbapenem, aggravates colonic GVHD in mice via the expansion of Bacteroides thetaiotaomicron (BT). BT has a broad ability to degrade dietary polysaccharides and host mucin glycans. BT in meropenem-treated allogeneic mice demonstrated upregulated expression of enzymes involved in the degradation of mucin glycans. These mice also had thinning of the colonic mucus layer and decreased levels of xylose in colonic luminal contents. Interestingly, oral xylose supplementation significantly prevented thinning of the colonic mucus layer in meropenem-treated mice. Specific nutritional supplementation strategies, including xylose supplementation, may combat antibiotic-mediated microbiome injury to reduce the risk for intestinal GVHD in allo-HSCT patients.
Indexed as
Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAnimalsAnti-Bacterial AgentsBacteroidesCarbapenemsMeropenemMiceMucinsMucusPolysaccharidesXyloseAnti-Bacterial AgentsCarbapenemsMeropenemMucinsPolysaccharidesXyloseallogeneic hematopoietic stem cell transplantationBacteroidesBacteroides thetaiotaomicronbroad-spectrum antibioticscarbapenemgraft-versus-host diseaseintestinal microbiomemucus-degrading bacteriamucus layerxylose
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07791849ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.